The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Open accessAbstract
Background & aims Agents that induce an immune response against tumors by altering T-cell regulation have increased survival times of patients with advanced-stage tumors, such as melanoma or lung cancer. We aimed to characterize molecular features of immune cells that infiltrate hepatocellular carcinomas (HCCs) to determine whether these types of agents might be effective against liver tumors.Methods We analyzed HCC samples from 956 patients. We separated gene expression profiles from tumor, stromal, and immune cells using a non-negative matrix factorization algorithm. We then analyzed the gene expression pattern of inflammatory cells in HCC tumor samples. We correlated expression patterns with the presence of immune cell infiltrates and immune regulatory molecules, determined by pathology and immunohistochemical analyses, in a training set of 228 HCC samples. We validated the correlation in a validation set of 728 tumor samples. Using data from 190 tumors in the Cancer Genome Atlas, we correlated immune cell gene expression profiles with numbers of chromosomal aberrations (based on single-nucleotide polymorphism array) and mutations (exome sequence data).Results We found approximately 25% of HCCs to have markers of an inflammatory response, with high expression levels of the CD274 molecule (programmed death-ligand 1) and programmed cell death 1, markers of cytolytic activity, and fewer chromosomal aberrations. We called this group of tumors the Immune class. It contained 2 subtypes, characterized by markers of an adaptive T-cell response or exhausted immune response. The exhausted immune response subclass expressed many genes regulated by transforming growth factor beta 1 that mediate immunosuppression. We did not observe any differences in numbers of mutations or expression of tumor antigens between the immune-specific class and other HCCs.Conclusions In an analysis of HCC samples from 956 patients, we found almost 25% to express markers of an inflammatory response. We identified 2 subclasses, characterized by adaptive or exhausted immune responses. These findings indicate that some HCCs might be susceptible to therapeutic agents designed to block the regulatory pathways in T cells, such as programmed death-ligand 1, programmed cell death 1, or transforming growth factor beta 1 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Inflamed tumours constitute ~30% of HCCs and exhibit extensive immune cell infiltration and immune activity, detected as increased expression of immune checkpoints (such as PD-1 or its ligand PD-L1), activation of IFN signalling and a low burden of large chromosomal alterations70,71,78.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [71]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, a high TMB does not correlate with increased immune infiltration70,71.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Flagged first, then by citations
2 of the 46 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–600 of 1,000
Nevi, L., Aiello, C., Molinaro, F., Altomare, A., Musarra, T., Gallo, P., Taffon, C., Guarino, M. P. L., Gentilucci, U. V., Baiocchini, A., et al. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00038-8 · Cited by 13
Federico, P., Giunta, E. F., Tufo, A., Tovoli, F., Petrillo, A., & Daniele, B. (2022) · Cancers · doi:10.3390/cancers14246245 · Cited by 10
Balcar, L., Bauer, D. J. M., Pomej, K., Meischl, T., Mandorfer, M., Reiberger, T., Trauner, M. A., Scheiner, B., & Pinter, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282680 · Cited by 10
Zemánek, T., Nová, Z., & Nicodemou, A. (2023) · Physiological Research · doi:10.33549/physiolres.935155 · Cited by 10
Ji, D., Lu, S., Zhang, H., Li, Z., Wang, S., Miao, T., Jiang, Z., & Ao, L. (2024) · Liver International · doi:10.1111/liv.15828 · Cited by 10
Wang, M., Zou, F., Wang, S., Yang, Y., Xia, C., Chen, L., Liu, B., Li, L., Li, M. J., Li, H., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3196 · Cited by 10
Expression landscape of epigenetic genes in human hepatocellular carcinoma
Castelló-Uribe, B., López-Pascual, A., Elurbide, J., Adán-Villaescusa, E., Valbuena-Goiricelaya, E., Martínez‐Pérez, L. A., Uriarte, I., Latasa, M. U., Sangro, B., Arechederra, M., et al. (2025) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-025-01095-6 · Cited by 11
Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review
Akabane, M., Chatzipanagiotou, O. P., Imaoka, Y., Schenk, A. D., & Pawlik, T. M. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s528709 · Cited by 10
Lin, S., Song, Z., Chen, P., Yu, X., Xie, W., Hua, Y., Li, S., Shen, S., & Kuang, M. (2025) · Liver Cancer · doi:10.1159/000547725 · Cited by 10
The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma
Warricker, F., Khakoo, S. I., & Blunt, M. D. (2021) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2021.27 · Cited by 11
Cherkassky, L., Oshi, M., Abdelfatah, E., Wu, R., Takabe, Y. J., Yan, L., Endo, I., & Takabe, K. (2022) · PubMed Central · Cited by 10
Cong, T., Luo, Y., Liu, Y., Yang, C., Yang, H., Li, Y., Li, J., & Li, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1000997 · Cited by 10
Novel Molecular Targets for Immune Surveillance of Hepatocellular Carcinoma
Guerra, P., Martini, A., Pontisso, P., & Angeli, P. (2023) · Cancers · doi:10.3390/cancers15143629 · Cited by 11
Zheng, Z., Wen, Y., Nie, K., Tang, S., Xu, C., Lan, S., Pan, J., Jiang, K., Jiang, X., Liu, P., et al. (2020) · Hepatology Research · doi:10.1111/hepr.13538 · Cited by 10
Current issues in the prevalence, diagnosis and management of hepatocellular carcinoma in Australia
Lubel, J. S., Roberts, S. K., Howell, J. A., Ward, J. S., & Shackel, N. A. (2021) · Internal Medicine Journal · doi:10.1111/imj.15184 · Cited by 10
Li, T., Zhang, Z., Wang, Y., Xu, D., Dong, J., Zhu, Y., & Wang, Z. (2021) · Journal of Cancer · doi:10.7150/jca.54408 · Cited by 10
N6-methyladenosine (m6A) regulatory gene divides hepatocellular carcinoma into three subtypes
Wei, J., Fang, D. L., Zhou, W., & He, Y. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-378 · Cited by 10
Yang, S., Cheng, Y., Wang, X., Wei, P., Wang, H., & Tan, S. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.777931 · Cited by 10
Jee, B., Seo, E., Park, K., Kim, Y. R., Byeon, S., Lee, S. M., Chung, J. H., Song, W., Sung, H. H., Jeon, H. G., et al. (2022) · Cancers · doi:10.3390/cancers14102354 · Cited by 10
de Mattos, Â. Z., Debes, J. D., Vogel, A., Arrese, M. A., Revelo, X. S., Pase, T. H. S., Manica, M., & de Mattos, Â. A. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i28.3595 · Cited by 10
Pâslaru, L., Bindea, G., Năstase, A., Sorop, A., Zimbru, C. G., Herlea, V., Hrehoreţ, D., Brașoveanu, V., Zamfir, R., Dima, S., et al. (2022) · Medicina · doi:10.3390/medicina58121803 · Cited by 10
Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
Kudo, M. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-203 · Cited by 10
Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data
Tornesello, M. L., Tornesello, A. L., Starita, N., Cerasuolo, A., Izzo, F., Buonaguro, L., & Buonaguro, F. M. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2147062 · Cited by 9
Tamura, Y., Ono, A., Nakahara, H., Hayes, C. N., Fujii, Y., Zhang, P., Yamauchi, M., Uchikawa, S., Teraoka, Y., Uchida, T., et al. (2023) · Cancers · doi:10.3390/cancers15174234 · Cited by 9
Gao, J., Han, S., Gu, J., Wu, C., & Mu, X. (2023) · Medicina · doi:10.3390/medicina59091682 · Cited by 9
Zhang, X., Xiao, Z., Zhang, X., Li, N., Sun, T., Zhang, J., Kang, C., Fan, S., Dai, L., & liu, X. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03242-3 · Cited by 9
Ouyang, J., Yang, Y., Zhou, Y., Xu, C., Wang, Z., Li, Q., Tang, Y., Cai, J., Zhou, J., Huang, Z., et al. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-363 · Cited by 9
Saleh, Y., Hejleh, T. A., Abdelrahim, M., Shamseddine, A. I., Chehade, L., Alawabdeh, T., Mohamad, I., Sammour, M., & Turfa, R. (2024) · Cancers · doi:10.3390/cancers16112081 · Cited by 10
Ji, Y., An, Q., Wen, X., Xu, Z., Xia, Z., Xia, Z., Hu, Q., & Lei, S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05855-7 · Cited by 9
Macdonald, J. K., Taylor, H. B., Wang, M., DelaCourt, A. T., Edge, C., Lewin, D., Kubota, N., Fujiwara, N., Rasha, F. A., Marquez, C. A., et al. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00099 · Cited by 9
Self-citationJiang, A., Liu, Y., He, Z., Liu, W., Yang, Q., Fang, Y., Zhu, B., Wu, X., Ye, H., Ye, B., et al. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.07.002 · Cited by 9
Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC
Piqué‐Gili, M., Andreu-Oller, C., Mesropian, A., Esteban-Fabró, R., Bárcena‐Varela, M., de Galarreta, M. R., Montironi, C., Martinez-Quetglas, I., Cappuyns, S., Peix, J., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101212 · Cited by 9
Self-citationHu, L., Wang, Z., Liao, Y., Jiang, X., Lian, H., & Lin, Z. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000041 · Cited by 9
Kuwano, A., TANAKA, K., Takahira, J., Suzuki, H., Ohishi, Y., & Motomura, K. (2024) · In Vivo · doi:10.21873/invivo.13757 · Cited by 10
Myeloid cell path to malignancy: insights into liver cancer
Ramirez, C. F. A., & Akkari, L. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.02.006 · Cited by 11
Harnessing immunotherapy for hepatocellular carcinoma: Principles and emerging promises
Miri, H., Rahimzadeh, P., Hashemi, M., Nabavi, N., Aref, A. R., Daneshi, S., Razzaghi, A., Abedi, M., Tahmasebi, S., Farahani, N., et al. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155928 · Cited by 9
Ma, C., Yu, X., Zhang, X., Su, L., Jiang, O., & Cui, R. (2025) · Oncology Letters · doi:10.3892/ol.2025.15088 · Cited by 9
Mesropian, A., Gris‐Oliver, A., Balaseviciute, U., Potdar, A. A., Kimura, T., Shen, J., Torres-Marcén, M., Abril‐Fornaguera, J., Piqué‐Gili, M., Camell-Raventos, D., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0725 · Cited by 10
Self-citationAkabane, M., Imaoka, Y., Lee, G. R., & Pawlik, T. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2568904 · Cited by 10
Wang, Y., Guan, Y., Abbas, A. R., Sano, Y., Jain, S., Lu, S., Hamidi, H., Koeppen, H., Azuma, Y., Kayukawa, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102473 · Cited by 9
Self-citationLiu, Y. (2025) · Liver Cancer · doi:10.1159/000550163 · Cited by 12
Zhou, W., Chen, Y., Luo, R., Li, Z., Jiang, G., & Ou, X. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.601693 · Cited by 9
Yu, J., Ma, S., Tian, S., Zhang, M., Ding, X., Liu, Y., Yang, F., Hu, Y., Xuan, G., Zhou, X., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.700553 · Cited by 9
Zhang, Q., Cao, W., Yang, C., Hong, L., Geng, S., Han, H., & Zhong, C. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109226 · Cited by 9
Liu, L., Wang, Q., Wu, L., Zhang, L., Huang, Y., Yang, H., Guo, L., Fang, Z., & Wang, X. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02949-z · Cited by 9
Immunotherapy for Advanced Hepatocellular Carcinoma-a Large Tertiary Center Experience
Raj, R., Aykun, N., Wehrle, C. J., Maspero, M., Krishnamurthi, S., Estfan, B. N., Kamath, S. D., & Aucejo, F. (2023) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-023-05783-w · Cited by 9
She, M., Wu, Y., Cheng, M., Feng, S., Li, G., & Rong, H. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1401139 · Cited by 9
Oshi, M., Chida, K., Roy, A. M., Mann, G. K., An, N., Yan, L., Endo, I., & Takabe, K. (2024) · Hepatology International · doi:10.1007/s12072-024-10678-2 · Cited by 9
Lyu, X., Wang, P., Qiao, Q., & Jiang, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08350-1 · Cited by 9
In vitro 3D liver tumor microenvironment models for immune cell therapy optimization
Lam, M. S. Y., Reales‐Calderón, J. A., Ow, J. R., Adriani, G., & Pavesi, A. (2021) · APL Bioengineering · doi:10.1063/5.0057773 · Cited by 9
Emerging Insights on Immunotherapy in Liver Cancer
Zhang, Y., Zhang, X., Kuang, M., & Yu, J. Q. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0047 · Cited by 9
Salani, F., Genovesi, V., Vivaldi, C., Massa, V., Cesario, S., Bernardini, L., Caccese, M., Graziani, J., Berra, D., Fornaro, L., et al. (2022) · Cancers · doi:10.3390/cancers14194896 · Cited by 10
Qi, X., Guo, J., Chen, G., Fang, C., Hu, L., Li, J., & Zhang, C. (2022) · Journal of Immunology Research · doi:10.1155/2022/3393027 · Cited by 9
Li, L., Liu, H.-T., Teng, Y., Deng, Z., Zhang, G.-L., Su, J., Ma, L., & Zhong, J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2151891 · Cited by 9
Chen, W., Zhang, X., Bi, K., Zhou, H., Xu, J. X., Dai, Y., & Diao, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554165 · Cited by 9
Amaro, C. P., & Tam, V. C. (2020) · Current Oncology · doi:10.3747/co.27.7103 · Cited by 9
Chen, H., Li, Y., Xiao, S., & Guo, J. (2021) · BMC Cancer · doi:10.1186/s12885-021-08012-2 · Cited by 9
Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma
Sharma, R., & Aval, L. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652007 · Cited by 10
Epigenetic mechanisms of liver tumor resistance to immunotherapy
Sanceau, J., & Gougèlet, A. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i9.979 · Cited by 10
Intratumoral microbiota in HCC: A new kid on the block?
Ji, J., Ji, F., & Bayarsaikhan, E. (2023) · Hepatology · doi:10.1097/hep.0000000000000454 · Cited by 9
Freedman, A. N., Roell, K. R., Engwall, E., Bulka, C. M., Kuban, K., Herring, L. E., Mills, C. A., Parsons, P. J., Galusha, A. L., O’Shea, T. M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914977 · Cited by 8
Marsh‐Wakefield, F., Santhakumar, C., Ferguson, A. L., Ashhurst, T. M., Shin, J., Guan, F. H. X., Shields, N. J., Platt, B. J., Putri, G., Gupta, R., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000540 · Cited by 8
Advancements in immunotherapy for hepatocellular carcinoma
Ascari, S., Chen, R., Vivaldi, C., Stefanini, B., Sinno, A. D., Dalbeni, A., Federico, P., & Tovoli, F. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2461631 · Cited by 8
USO1 isoforms differentially promote liver cancer progression by dysregulating the ER–Golgi network
Yoon, S., Choi, J. H., Shah, M., Kwon, S. M., Yang, J., Park, Y. N., Wang, H.-J., & Woo, H. G. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab067 · Cited by 8
Wei, Z., Duan, X., Li, Q., Li, Q., & Wang, Y. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-541 · Cited by 8
Zheng, Z., Hu, Y., Ren, Y., Mo, G., & Wan, H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0267809 · Cited by 9
New progress with calcium-binding protein S100A16 in digestive system disease
Li, B., Zhu, W., Shi, D., Che, H., Lyu, Q., & Jiang, B. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2174968 · Cited by 8
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma
Pinato, D. J., Kaneko, T., D’Alessio, A., Forner, A., Fessas, P., Mínguez, B., Giannini, E. G., Grillo, F., Díaz, A., Mauri, F. A., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100741 · Cited by 8
Self-citationKurebayashi, Y., Tsujikawa, H., Sugimoto, K., Yunaiyama, D., Araki, Y., Saito, K., Takahashi, H., Kakegawa, T., Wada, T., Tomita, Y., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13933 · Cited by 8
Dantzer, C., Vaché, J., Brunel, A., Mahouche, I., Raymond, A., Dupuy, J., Petrel, M., Bioulac‐Sage, P., Perrais, D., Dugot‐Senant, N., et al. (2024) · eLife · doi:10.7554/elife.95191 · Cited by 8
SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)
López, C., Calvo, M., Cámara, J. C., García-Paredes, B., Gómez-Martín, C., López, A. M., Pazo-Cid, R., Sastre, J., Yayá, R., & Feliú, J. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03568-4 · Cited by 8
Getting insights into hepatocellular carcinoma tumour heterogeneity by multiomics dissection
Sarobe, P., & Corrales, F. J. (2019) · Gut · doi:10.1136/gutjnl-2019-319410 · Cited by 8
Feng, Z., Xu, F., Liu, Y., Xu, H., Wu, F., Chen, X., & Xia, H. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2020.107 · Cited by 8
Shimada, S., & Tanaka, S. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02174-0 · Cited by 6
Jin, X., Zhang, K., Fang, T., Zeng, X., Xu, Y., Tang, J., Liang, Z., Xie, L., & Zhao, D. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.951303 · Cited by 8
Güven, D. C., Erul, E., Şahin, T. K., Dızdar, Ö., Yalçın, Ş., & Şahin, İ. H. (2022) · Future Oncology · doi:10.2217/fon-2022-0642 · Cited by 9
Frequent expression of PD-L1 in lymphocyte-rich hepatocellular carcinoma: A report of 4 cases
Vij, M., Veerankutty, F. H., Raju, L. P., Gowrishankar, G., Rajalingam, R., Jothimani, D. K., Kaliamoorthy, I., Rammohan, A., & Rela, M. (2023) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2023.152172 · Cited by 8
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
Kudo, M. (2023) · Liver Cancer · doi:10.1159/000531225 · Cited by 8
Genetics of alcohol-related hepatocellular carcinoma - its role in risk prediction
Liu, K., Verset, G., Trépo, E., & Seth, D. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.25 · Cited by 8
Kim, H.-R., Seo, C.-W., & Kim, J. (2023) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2023.0229 · Cited by 7
Pourbagheri‐Sigaroodi, A., Momeny, M., Rezaei, N., Fallah, F., & Bashash, D. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4098 · Cited by 7
Ye, K., Yan, Y.-F., Su, R., Dai, Q., Qiao, K., Cao, Y., Xu, J. C., Yan, L., Huo, Z., Liu, W., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00853-w · Cited by 7
Glycolytic reprogramming in macrophage polarization: New horizons in the treatment of tumor diseases
Wang, D., & Guan, H. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111940 · Cited by 8
Scheiner, B., Lombardi, P., D’Alessio, A., Kim, G., Tafavvoghi, M., Petrenko, O., Goldin, R. D., Fulgenzi, C. A. M., Torkpour, A., Balcar, L., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010975 · Cited by 7
Jin, X., Ma, X., Zhao, D. F., Yang, L., & Ma, N. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101603 · Cited by 7
Wan, S., Zhao, E., Freeman, D., Weissinger, D., Krantz, B. A., Werba, G., Khanna, L. G., Siolas, D., Oberstein, P. E., Chattopadhyay, P. K., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1067352 · Cited by 7
Zhou, Y., Chen, R., Zheng, S., Li, X., Zhou, Y., & Zhou, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1076587 · Cited by 7
Minamiguchi, K., Irizato, M., Uchiyama, T., Taiji, R., Nishiofuku, H., Marugami, N., & Tanaka, T. (2023) · European Radiology · doi:10.1007/s00330-023-09950-0 · Cited by 7
Lin, S., Li, D., Yang, Y., Yu, M., Zhao, R., Li, J., & Peng, L. (2024) · Journal of Cancer · doi:10.7150/jca.92185 · Cited by 8
Radio-immunomics in hepatocellular carcinoma: Unraveling the tumor immune microenvironment
Liu, Q., Zhu, W., Song, F., Lou, T., He, L., Zhou, W., & Feng, Z. (2024) · Meta-Radiology · doi:10.1016/j.metrad.2024.100098 · Cited by 7
Murata, Y., Nosaka, T., Akazawa, Y., Tanaka, T., Takahashi, K., Naito, T., Matsuda, H., Ohtani, M., & Nakamoto, Y. (2024) · Cancers · doi:10.3390/cancers16132410 · Cited by 7
Intratumoral microbiota: an emerging force in diagnosing and treating hepatocellular carcinoma
Liu, H., Zhang, J., Rao, Y., Jin, S., Zhang, C., & Bai, D. (2024) · Medical Oncology · doi:10.1007/s12032-024-02545-9 · Cited by 9
Celsa, C., Quartararo, A., Maida, M. F., Giusino, G., Gaudioso, V., Sparacino, A., Cusimano, G., Rao, S., Grova, A., Ciccia, R., et al. (2025) · Hepatoma Research · doi:10.20517/2394-5079.2024.126 · Cited by 7
Shupeng, L., Zaixin, Z., Jia, Y., Jie, X., Liu, Z., Kai, C., Shuqun, C., & Shanrong, L. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0184 · Cited by 7
Hepatocellular carcinoma: Clinicopathologic associations amidst marked phenotypic heterogeneity
Rastogi, A., Maiwall, R., Ramakrishna, G., Modi, S., Taneja, K., Bihari, C., Kumar, G., Patil, N. S., Thapar, S., Choudhury, A. K., et al. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153290 · Cited by 7
Translational Research in Cancer
Sundaresan, S., & Gu, Y. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.73772 · Cited by 8
Hernáez, R., & Avila, M. A. (2022) · Gut · doi:10.1136/gutjnl-2022-327132 · Cited by 7
Wang, H., Yu, L., Cui, Y., & Huang, J. (2022) · Disease Markers · doi:10.1155/2022/1313359 · Cited by 7
RetractedShen, Q., He, Y., Qian, J., & Wang, X. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.960457 · Cited by 7
Cui, X., Han, L., Cui, L., Fu, G., Liu, E., Wang, D., Song, B., Zhang, Y., Zhou, W., Wang, H., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106583 · Cited by 7
Metadata
- Authors
- Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., Losic, B., Waxman, S., Thung, S. N., Mazzaferro, V., Esteller, M., Friedman, S. L., Schwartz, M., Villanueva, A., & Llovet, J. M.
- Affiliations
- Tisch Cancer Institute (US)
- Hospital Clínic de Barcelona (ES)
- University of Milan (IT)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Llovet, Josep M.
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 153
- Issue
- 3
- Pages
- 812-826
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC12166766
- OpenAlex
- W2626033245
- Cited by
- 976
- References
- 46
- Citations by year
- 2026: 65 · 2025: 82 · 2024: 124 · 2023: 136 · 2022: 155 · 2021: 188 · 2020: 104 · 2019: 72 · 2018: 41 · 2017: 9
- FWCI
- 27.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Gastroenterology (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (acceptedVersion, cc-by-nc-nd)
- Funders
- Tisch Cancer Institute (P30 CA196521)
- US Department of Defense (CA150272P3)
- European Commission Framework Program 7 (259744)
- Horizon 2020 Program (667273–2)
- Asociación Española Contra el Cáncer
- Samuel Waxman Cancer Research Foundation
- Spanish National Health Institute (SAF2013–41027)
- Grup de Recerca Consolidat–Recerca Translacional en Oncologia Hepàtica
- AGAUR (SGR 1162)
- European Commission HEPCAR
- Onlus Prometeo
- Hepato-Oncology Research Project
- Istituto Nazionale Tumori
- National Cancer Institute
- IRCCS Foundation
- Juan de la Cierva Fellowship
- Associazione Italiana per la Ricerca sul Cancro
- Italian Ministry of Health
- National Institutes of Health (R01DK56621)
- American Association
- Liver Diseases Foundation Alan Hofmann Clinical and Translational Award
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, tumor immune microenvironment, immune cell infiltration, PD-1, T cell exhaustion, TGF-β1, chromosomal abnormalities, cancer mutations, tumor-infiltrating immune cells, immune checkpoint inhibitors, tumor subtypes, gene expression profiling, non-negative matrix factorization, tides
- MeSH terms
- Aged, Female, Carcinoma, Hepatocellular, Humans, Immune Tolerance, Immunohistochemistry, Liver Neoplasms, Male, Middle Aged, Mutation, Signal Transduction, Gene Expression Regulation, Neoplastic, Immunophenotyping, Lymphocytes, Tumor-Infiltrating, DNA Methylation, beta Catenin, Transforming Growth Factor beta1, Adaptive Immunity, Tumor Microenvironment, Transcriptome, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
